Omeros reports Phase II OS data for OMS721 in thrombotic microangiopathy

By Elizabeth S. Eaton | Mar 16, 2018 | 4:13 PM GMT

Omeros Corp. (NASDAQ:OMER) reported data from 18 patients with hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy